163
Views
15
CrossRef citations to date
0
Altmetric
Review

Treatment of children and adolescents with multiple sclerosis

Pages 391-401 | Published online: 10 Jan 2014

References

  • Lublin FD. The diagnosis of multiple sclerosis. Curr. Opin. Neurol. 15, 253–256 (2002).
  • O’Connor P. Key issues in the diagnosis and treatment of multiple sclerosis. An overview. Neurology 59, S1–33 (2002).
  • vanderMie I, Ponsonby AL, Dwyer T et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. Br. Med. J. 327, 316 (2003).
  • DeLuca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J. 15, 2579–2585 (2001).
  • Meehan TF, DeLuca HF. The vitamin D receptor is necessary for 1α, 25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch. Biochem. Biophys. 408, 200–204 (2002).
  • Holick MF. Vitamin D: a millenium perspective. J. Cell. Biochem. 88, 296–307 (2003).
  • Ascherio A, Munch M. Epstein–Barr virus and multiple sclerosis. Epidemiology 11, 220–224 (2000).
  • Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B. Epstein–Barr virus in pediatric multiple sclerosis. JAMA 291, 1875–1879 (2004).
  • Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D. Early onset multiple sclerosis: a longitudinal study. Neurology 59, 1006–1010 (2002).
  • Boutin B, Esquivel E, Mayer M, Chaumet S, Ponsot G, Arthuis M. Multiple sclerosis in children: report of clinical and paraclinical features of 19 cases. Neuropediatrics 19, 118–123 (1988).
  • Cole GF, Stuart CA. A long perspective on childhood multiple sclerosis. Dev. Med. Child Neurol. 37, 661–666 (1995).
  • Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 12, 2407–2422 (2000).
  • Duquette P, Murray TJ, Pleines J et al. Multiple sclerosis in childhood: clinical profile in 125 patients. J.Pediatr. 111, 359–363 (1987).
  • Gall J, Hayles A, Siekert R, Keith H. Multiple sclerosis in children: a clinical study of 40 cases with onset in childhood. Pediatrics 21, 703–709 (1958).
  • Ghezzi A, Deplano V, Faroni J et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult. Scler. 3, 43–46 (1997).
  • Guilhoto LM, Osorio CA, Machado LR et al. Pediatric multiple sclerosis report of 14 cases. Brain Dev. 17, 9–12 (1995).
  • Gusev E, Boiko A, Bikova O et al. The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clin. Neurol. Neurosurg. 104, 203–207 (2002).
  • Pinhas-Hamiel O, Barak Y, Siev-Ner I, Achiron A. Juvenile multiple sclerosis: clinical features and prognostic characteristics. J. Pediatr. 132, 735–737 (1998).
  • Ozakbas S, Idiman E, Baklan B, Yulug B. Childhood and juvenile onset multiple sclerosis: clinical and paraclinical features. Brain Dev. 25, 233–236 (2003).
  • Selcen D, Anlar B, Renda Y. Multiple sclerosis in childhood: report of 16 cases. Eur. Neurol. 36, 79–84 (1996).
  • Simone IL, Carrara D, Tortorella C et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 59, 1922–1928 (2002).
  • Sindern E, Haas J, Stark E, Wurster U. Early onset MS under the age of 16: clinical and paraclinical features. Acta Neurol. Scand. 86, 280–284 (1992).
  • Hanefeld F, Bauer HJ, Christen HJ, Kruse B, Bruhn H, Frahm J. Multiple sclerosis in childhood: report of 15 cases. Brain Dev. 13, 410–416 (1991).
  • Ghezzi A, Pozzilli C, Liguori M et al. Prospective study of multiple sclerosis with early onset. Mult. Scler. 8, 115–118 (2002).
  • Ruggieri M, Polizzi A, Pavone L, Grimaldi LM. Multiple sclerosis in children under 6 years of age. Neurology 53, 478–484 (1999).
  • Banwell BL. Pediatric multiple sclerosis. Curr. Neurol. Neurosci. Rep. 4, 245–252 (2004).
  • Boiko AN, Guseva ME, Guseva MR et al. Clinico-immunogenetic characteristics of multiple sclerosis with optic neuritis in children. J. Neurovirol. 6(Suppl. 2), S152–S155 (2000).
  • Mikaeloff Y, Suissa S, Vallee L et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J. Pediatr. 144, 246–252 (2004).
  • Hanefeld F. Multiple sclerosis in childhood. Curr. Opin. Neurol. Neurosurg. 5, 359–363 (1992).
  • Lucchinetti CF, Kiers L, O’Duffy A et al. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology 49, 1413–1418 (1997).
  • Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53, 1107–1114 (1999).
  • Jeffery AR, Buncic JR. Pediatric Devic’s neuromyelitis optica. J. Pediatr. Ophthalmol. Strabismus. 33, 223–229 (1996).
  • Lennon VA, Wingerchuk DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364, 2106–2112 (2004).
  • Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 59, 1224–1231 (2002).
  • Wingerchuk DM. Postinfectious encephalomyelitis. Curr. Neurol. Neurosci. Rep. 3, 256–264 (2003).
  • Lucchinetti CF, Brueck W, Rodriguez M, Lassmann H. Multiple sclerosis: lessons from neuropathology. Semin. Neurol. 18, 337–349 (1998).
  • Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol.. 12, 295–302 (1999).
  • Trapp BD, Bo L, Mork S, Chang A. Pathogenesis of tissue injury in MS lesions. J. Neuroimmunol. 98, 49–56 (1999).
  • Yong VW. Prospects for neuroprotection in multiple sclerosis. Front Biosci. 9, 864–872 (2004).
  • Wang HY, Matsui M, Araya S, Onai N, Matsushima K, Saida T. Immune parameters associated with early treatment effects of high-dose intravenous methylprednisolone in multiple sclerosis. J. Neurol. Sci. 216, 61–66 (2003).
  • Andersson PB, Goodkin DE. Glucocorticosteroid therapy for multiple sclerosis: a critical review. J. Neurol. Sci. 160, 16–25 (1998).
  • Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 49, 1404–1413 (1997).
  • Metz LM, Sabuda D, Hilsden RJ, Enns R, Meddings JB. Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis. Neurology 53, 2093–2096 (1999).
  • Morrow SA, Stoian CA, Dmitrovic J, Chan SC, Metz LM. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 63, 1079–1080 (2004).
  • Stangel M, Toyka KV, Gold R. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch. Neurol. 56, 661–663 (1999).
  • Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291, 2367–2375 (2004).
  • Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur. J. Neurol. 9, 557–563 (2002).
  • Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomized placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 349, 589–593 (1997).
  • Sorensen PS, Wanscher B, Jensen CV et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50, 1273–1281 (1998).
  • Achiron A, Kishner I, Sarova-Pinhas I et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch. Neurol. 61, 1515–1520 (2004).
  • Noseworthy JH, O’Brien PC, Petterson TM et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56, 1514–1522 (2001).
  • Hommes OR, Sorensen PS, Fazekas F et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364, 1149–1156 (2004).
  • Visser LH, Beekman R, Tijssen CC et al. A randomized, double-blind, placebo-controlled pilot study of intravenous immune globulins in combination with intravenous methylprednisolone in the treatment of relapses in patients with MS. Mult. Scler. 10, 89–91 (2004).
  • Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 63, 2028–2033 (2004).
  • Hahn JS, Siegler DJ, Enzmann D. Intravenous gammaglobulin therapy in recurrent acute disseminated encephalomyelitis. Neurology 46, 1173–1174 (1996).
  • Nishikawa M, Ichiyama T, Hayashi T, Ouchi K, Furukawa S. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. Pediatr. Neurol. 21, 583–586 (1999).
  • Murthy SN, Faden HS, Cohen ME, Bakshi R. Acute disseminated encephalomyelitis in children. Pediatrics 110, e21 (2002).
  • Pradhan S, Gupta RP, Shashank S, Pandey N. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. J. Neurol. Sci. 165, 56–61 (1999).
  • Apak RA, Anlar B, Saatci I. A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment. Brain Dev. 21, 279–282 (1999).
  • Sahlas DJ, Miller SP, Guerin M, Veilleux M, Francis G. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology 54, 1370–1372 (2000).
  • Finsterer J, Grass R, Stollberger C, Mamoli B. Immunoglobulins in acute, parainfectious, disseminated encephalo-myelitis. Clin. Neuropharmacol. 21, 258–261 (1998).
  • Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus. Med. Rev. 17, 241–251 (2003).
  • Weinshenker BG, O’Brien PC, Petterson TM et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann. Neurol. 46, 878–886 (1999).
  • Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann. Neurol. 37, 7–15 (1995).
  • Yong VW, Chabot S, Stuve O, Williams G. Interferon β in the treatment of multiple sclerosis: mechanisms of action. Neurology 51, 682–689 (1998).
  • The IFN-B Multiple Sclerosis Study Group. Interferon β1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 655–661 (1993).
  • Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39, 285–294 (1996).
  • PRISMS. Randomised double-blind placebo-controlled study of interferon β1a in relapsing-remitting ms. Lancet 352, 1498–1504. (2000).
  • PRISMS4. Long-term efficacy of interferon-β1a in relapsing MS. Neurology 56, 1628–1636 (2001).
  • Durelli L, Verdun E, Barbero P et al. Every-other-day interferon β1b versus once-weekly interferon β1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359, 1453–1460 (2002).
  • Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP. A prospective, open-label treatment trial to compare the effect of IFN-β1a (Avonex®), IFN-β1b (Betaseron®), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Mult. Scler. 7, 349–353 (2001).
  • Rudick RA. Biologic impact of interferon antibodies, and complexities in assessing their clinical significance. Neurology 61, S31–S34 (2003).
  • Bertolotto A, Gilli F, Sala A et al. Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients. Neurology 60, 634–639 (2003).
  • Vartanian TK, Zamvil SS, Fox E, Sorensen PS. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology 63, S42–S49 (2004).
  • Adams AB, Tyor WR, Holden KR. Interferon β1b and childhood multiple sclerosis. Pediatr. Neurol.21, 481–483 (1999).
  • Etheridge LJ, Beverley DW, Ferrie C, McManus E. The use of interferon β in relapsing-remitting multiple sclerosis. Arch. Dis. Child. 89, 789–791 (2004).
  • Mikaeloff Y, Moreau T, Debouverie M et al. Interferon-β treatment in patients with childhood-onset multiple sclerosis. J. Pediatr. 139, 443–446 (2001).
  • Waubant E, Hietpas J, Stewart T et al. Interferon β1a in children with multiple sclerosis is well-tolerated. Neuropediatrics 32, 211–213 (2001).
  • Pohl D, Rostasy K, Hanefeld F, Gartner J. The use of interferon-β1a (Rebif) in children and adolescents with multiple sclerosis. Mult. Scler. 10(Suppl. 2), 250 (2004).
  • Krupp LB, Banwell BL, Boiko A et al. Treatment of childhood and adolescent MS with interferon-β1b. Mult. Scler. 10(Suppl. 2), 245 (2004).
  • Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon β1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 343, 898–904 (2000).
  • Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357, 1576–1582 (2001).
  • Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56, 702–708 (2001).
  • Johnson KP, Brooks BR, Cohen JA et al. Co-polymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. The co-polymer 1 Multiple Sclerosis Study Group. Neurology 45, 1268–1276 (1995).
  • Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 49, 290–297 (2001).
  • Johnson KP, Brooks BR, Ford CC et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Co-polymer 1 Multiple Sclerosis Study Group. Mult. Scler. 6, 255–266 (2000).
  • Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane. Database. Syst. Rev. CD004678 (2004).
  • Millefiorini E, Gasperini C, Pozzilli C et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J. Neurol. 244, 153–159 (1997).
  • Hartung HP, Gonsette R, Konig N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360, 2018–2025 (2002).
  • The Canadian Co-operative Multiple Sclerosis Study Group. The Canadian co-operative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337, 441–446 (1991).
  • Weiner HL, Mackin GA, Orav EJ et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Co-operative Multiple Sclerosis Treatment Group. Neurology 43, 910–918 (1993).
  • Smith D. Preliminary analysis of a trial of pulse cyclophosphamide in IFN-β-resistant active MS. J. Neurol. Sci. 223, 73–79 (2004).
  • Hauser SL, Dawson DM, Lehrich JR et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N. Engl. J. Med. 308, 173–180 (1983).
  • Yudkin PL, Ellison GW, Ghezzi A et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 338, 1051–1055 (1991).
  • Confavreux C, Vukusic S. Non-specific immunosuppressants in the treatment of multiple sclerosis. Clin. Neurol. Neurosurg. 106, 263–269 (2004).
  • Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre Phase 2 study. J. Neurol. Neurosurg. Psychiatry 72, 179–183 (2002).
  • Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch. Neurol. 46, 676–680 (1989).
  • Hyman N, Barnes M, Bhakta B et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double-blind, placebo-controlled, dose ranging study. J. Neurol. Neurosurg. Psychiatry 68, 707–712 (2000).
  • Weinstock-Guttman B, Cohen JA. Emerging therapies for multiple sclerosis. Neurologist2, 342–355 (1996).
  • Solaro C, Lunardi GL, Capello E et al. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology 51, 609–611 (1998).
  • Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15–23 (2003).
  • Neuhaus O, Strasser-Fuchs S, Fazekas F et al. Statins as immunomodulators: comparison with interferon-β1b in MS. Neurology 59, 990–997 (2002).
  • Vollmer T, Key L, Durkalski V et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363, 1607–1608 (2004).
  • McCrindle BW, Helden E, Cullen-Dean G, Conner WT. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr. Res. 51, 715–721 (2002).
  • de Jongh S, Lilien MR, Op’t Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J. Am. Coll. Cardiol. 40, 2117–2121 (2002).
  • Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu. Rev. Med. 55, 477–503 (2004).
  • Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in Neurology. Lancet Neurol. 3, 744–751 (2004).

Websites

  • Sick kids: demyelination of the central nervous system in Canadian children http://pedsdemyelination.ccb.sickkids.ca (Accessed April 2005)
  • MS Society of Canada www.mssociety.ca/en/help/Young PersonsMS.htm (Accessed April 2005)
  • National MS Society www.nationalmssociety.org/peds_ network.asp (Accessed April 2005)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.